1. Clinical characteristics and immune profiles of patients with immune-mediated alopecia associated with COVID-19 vaccinations.
- Author
-
Wang CW, Wu MY, Chen CB, Lin WC, Wu J, Lu CW, Chen WT, Wang FY, Hui RC, Chi MH, Chiu TM, Chang YC, Lin JY, Lin YY, Tsai WT, Hung SI, and Chung WH
- Subjects
- Humans, COVID-19 Vaccines adverse effects, Spike Glycoprotein, Coronavirus, Vaccination adverse effects, COVID-19, Alopecia Areata etiology, Alopecia Areata pathology
- Abstract
Background: The clinical characteristics and pathomechanism for immune-mediated alopecia following COVID-19 vaccinations are not clearly characterized., Objective: We investigated the causality and immune mechanism of COVID-19 vaccines-related alopecia areata (AA)., Study Design: 27 new-onset of AA patients after COVID-19 vaccinations and 106 vaccines-tolerant individuals were enrolled from multiple medical centers for analysis., Results: The antinuclear antibody, total IgE, granulysin, and PARC/CCL18 as well as peripheral eosinophil count were significantly elevated in the patients with COVID-19 vaccines-related AA compared with those in the tolerant individuals (P = 2.03 × 10
-5 -0.039). In vitro lymphocyte activation test revealed that granulysin, granzyme B, and IFN-γ released from the T cells of COVID-19 vaccines-related AA patients could be significantly increased by COVID-19 vaccine excipients (polyethylene glycol 2000 and polysorbate 80) or spike protein (P = 0.002-0.04)., Conclusions: Spike protein and excipients of COVID-19 vaccines could trigger T cell-mediated cytotoxicity, which contributes to the pathogenesis of immune-mediated alopecia associated with COVID-19 vaccines., Competing Interests: Declaration of Competing Interest All authors have declared that they have no conflict of interest., (Copyright © 2023. Published by Elsevier Inc.)- Published
- 2023
- Full Text
- View/download PDF